Nantkwest Inc (NASDAQ:NK) Expected to Post Earnings of -$0.26 Per Share

Equities analysts expect Nantkwest Inc (NASDAQ:NK) to post earnings of ($0.26) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Nantkwest’s earnings. Nantkwest posted earnings per share of ($0.30) in the same quarter last year, which would indicate a positive year over year growth rate of 13.3%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 14th.

On average, analysts expect that Nantkwest will report full-year earnings of ($0.82) per share for the current financial year. For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.38) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Nantkwest.

Nantkwest (NASDAQ:NK) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.01. The firm had revenue of $0.01 million for the quarter. Nantkwest had a negative return on equity of 48.18% and a negative net margin of 125,903.34%.

A number of research firms have recently weighed in on NK. Citigroup downgraded Nantkwest from a “neutral” rating to a “sell” rating and cut their price target for the company from $1.25 to $1.00 in a research note on Thursday, May 30th. Zacks Investment Research downgraded Nantkwest from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Finally, ValuEngine raised Nantkwest from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. Nantkwest has a consensus rating of “Hold” and a consensus target price of $2.00.

NK traded up $0.02 during mid-day trading on Thursday, reaching $1.36. The stock had a trading volume of 193,111 shares, compared to its average volume of 250,427. The company has a market cap of $131.73 million, a PE ratio of -1.11 and a beta of 2.33. The company has a quick ratio of 4.09, a current ratio of 7.00 and a debt-to-equity ratio of 0.08. The stock has a fifty day moving average price of $1.18. Nantkwest has a 52 week low of $0.93 and a 52 week high of $4.23.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in shares of Nantkwest by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 328,877 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 8,961 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of Nantkwest in the 4th quarter valued at about $84,000. D. E. Shaw & Co. Inc. grew its holdings in shares of Nantkwest by 338.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 180,595 shares of the biotechnology company’s stock valued at $210,000 after acquiring an additional 139,431 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Nantkwest by 165.9% in the 4th quarter. Deutsche Bank AG now owns 149,330 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 93,170 shares in the last quarter. Finally, Edge Wealth Management LLC grew its holdings in shares of Nantkwest by 100.0% in the 1st quarter. Edge Wealth Management LLC now owns 20,000 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 10,000 shares in the last quarter. 8.05% of the stock is currently owned by hedge funds and other institutional investors.

Nantkwest Company Profile

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Featured Story: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on Nantkwest (NK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.